{"name":"Exact Sciences Corp.","slug":"exact-sciences","ticker":"EXAS","exchange":"NASDAQ","domain":"exactsciences.com","description":"Exact Sciences Corporation is an American molecular diagnostics company based in Madison, Wisconsin, specializing in the detection of early-stage cancers. The company provides products for the detection and prevention of colorectal cancer, including Cologuard, the first stool DNA test for colorectal cancer, along with additional screening and precision oncological tests for other types of cancer.","hq":"Madison, WI","founded":0,"employees":"7100","ceo":"Kevin Conroy","sector":"Diagnostics / Precision Oncology","stockPrice":104.91,"stockChange":0,"stockChangePercent":0,"marketCap":"$20.0B","metrics":{"revenue":3246990080,"revenueGrowth":23.1,"grossMargin":69.7,"rdSpend":522996000,"netIncome":-207949000,"cash":964710976,"dividendYield":0,"peRatio":55.2,"fiscalYear":"FY2013"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[{"date":"2024-02-27","type":"earnings","headline":"Exact Sciences Reports Fourth-Quarter and Full-Year 2023 Financial Results","summary":"Exact Sciences reported fourth-quarter and full-year 2023 financial results, with revenue of $1.3 billion and a net loss of $1.1 billion.","drugName":"","sentiment":"neutral"},{"date":"2023-11-15","type":"deal","headline":"Exact Sciences and Pfizer Announce Collaboration to Develop and Commercialize Non-Invasive Cancer Tests","summary":"Exact Sciences and Pfizer announced a collaboration to develop and commercialize non-invasive cancer tests, including a test for lung cancer.","drugName":"","sentiment":"positive"},{"date":"2023-08-01","type":"regulatory","headline":"FDA Approves Exact Sciences' Cologuard for Use in Patients with a Family History of Colorectal Cancer","summary":"The FDA approved Exact Sciences' Cologuard for use in patients with a family history of colorectal cancer.","drugName":"","sentiment":"positive"}],"realNews":[{"url":"https://news.google.com/rss/articles/CBMi2AFBVV95cUxNYjdtNjZxaDhkNnZCcmJBczFWNEZlZG1oWDVtVkQ3RU1kVlk4MmZSM2Rlbm9tcWliQ2Znd25UNy11c2tpVTlQaW5JTFN5MXdYTncySUJNM05tU1RkbW9wTVh5NmlBY1k4bzFoRjFvMEttWHBXQ0wxV2ZUUFMxbmlEdFE2dVA3TWwtQ0Y1dURoRGtsVU02cFpRQWpuT0tPbk1VS0lfMkpoMTdoXzFPUVBVcGlPWllNd0hfejczazhZX0ctaVpacEVBRDRQVnFEX1VJWjZRc2UzQnE?oc=5","date":"2026-03-23","type":"pipeline","source":"Proactive Investors","summary":"Inside Biotech: Big pharma splits its bets between certainty and risk - Proactive Investors","headline":"Inside Biotech: Big pharma splits its bets between certainty and risk","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2026-03-21","type":"pipeline","source":"simplywall.st","summary":"The Bull Case For Exact Sciences (EXAS) Could Change Following Walgreens’ Nationwide Cologuard Pharmacy Rollout - simplywall.st","headline":"The Bull Case For Exact Sciences (EXAS) Could Change Following Walgreens’ Nationwide Cologuard Pharmacy Rollout","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMisAFBVV95cUxQS2Q3a25aZG1WREJGUVpvQlFicnI3MEFwRGxjT3k0UEZGWGxIbXl5bUJvVmFleDB3VUpaaVQ1VTM3QzBuQ0Z2TVZycm5UaFZicjBIMXVBYUhsNDlrdTFRSVk0c0ViY09NOU9RX1g5MTRsWHd2WlpuU2RUTV92VHhoYnlnUjRXMWtLQW5Sc0RRTGw4dXphQVluUzN4Y2RYaWJ0eVNrWEtUSXFWYV9hd3I2bw?oc=5","date":"2026-03-21","type":"pipeline","source":"Yahoo Finance","summary":"How Walgreens’ Pharmacy-Led Cologuard Expansion At Exact Sciences (EXAS) Has Changed Its Investment Story - Yahoo Finance","headline":"How Walgreens’ Pharmacy-Led Cologuard Expansion At Exact Sciences (EXAS) Has Changed Its Investment Story","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMisAFBVV95cUxQVGJ2QTdOSlc2SnY1aXplZnJnZ3BnOHV6S2M1R0o1TG9nYlZLbktNWmR2Z3ZKQUM5ZzVtLTdsc2V0bGtwZm5FQTRCcXgtalAwQ2kyQzlaN01OWjhCdHlzdEgxNW1YSVE3QjY3dDhZVVc2OHBuMk5wODdQQzVZeDNFV0hiT1JpRnVFOXBsNWFTWlY1Q0JfRldpVTBmNUFxTm9yVVVXVVJMRktCS3J3VnMxZg?oc=5","date":"2026-02-27","type":"regulatory","source":"Finviz","summary":"Exact Sciences (EXAS) Merger with Abbott Moving Forward After Shareholder Approval - Finviz","headline":"Exact Sciences (EXAS) Merger with Abbott Moving Forward After Shareholder Approval","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMijAFBVV95cUxQT3lnVjB6eHV6MmpiWmEwSDV5aERoZlRzZndLNldKQnlndDJ4TTFCR0VSRWVrbzU1cHp6NnJMbkEtMUFLRG5PVlpEem1OdDczdllfQ05GbFJHSmxvUzFMdzBFQ2tRRlpMM1BiNERwZC1zQXVCdXhNbWVvWmZlaURFb3lwT1Voa19Lc2U2Vw?oc=5","date":"2026-02-08","type":"earnings","source":"Finviz","summary":"Exact Sciences (EXAS): Buy, Sell, or Hold Post Q3 Earnings? - Finviz","headline":"Exact Sciences (EXAS): Buy, Sell, or Hold Post Q3 Earnings?","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMisAFBVV95cUxQU1Z2MTRWSUVwbmlSclVJMkxYTXRTR0pJV1dEOGY1T0dYcHpoNjZ1a2hRVGsxQXlxSjhxTGJkVkRDV0t3YkF3Z0VrYWFuTmRhM180LXV1ZU9PbWNiMXc4emxoY191X2dvTUdQOUU2MWFLVlZrbmtlT0pid2lpZVdtLVlzZGYxc1drdXBZYkhBcnZFMDJSOWdaQk1ibGJVQWgxYi1tcGotbmViNmtfXzlGRQ?oc=5","date":"2026-01-02","type":"earnings","source":"Benzinga","summary":"Top 2 Health Care Stocks That May Crash In Q1 - Benzinga","headline":"Top 2 Health Care Stocks That May Crash In Q1","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMisAFBVV95cUxNUDQydlgyZ3gyd0R1YWNQbm9CZUNNcFlfOFN5Z1FxeUY5TllFeVpSekxhRW9YNkd2YUduRGdDVGQ5bVNQY2RCTDAzbUJKQVFFSC1HOGxGTFpzZjhXbzNsbldOLWNHZWg1cXdxU3BXclVwUFA2YUNQa3BkYVY4WHFJc19VNVJtVjJZaGUtTkFqbHAxUXBpZHUtdlg5SkExOWpteldjTVotbERwRXF3SVNPXw?oc=5","date":"2025-11-20","type":"pipeline","source":"Investopedia","summary":"Why the Stock Price of This Cancer Screening Company Soared 17% Thursday - Investopedia","headline":"Why the Stock Price of This Cancer Screening Company Soared 17% Thursday","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiogFBVV95cUxOM1RaU1ZleFJzQW0yNXBNQWVJUE9ydmdOTDNUTEJfLXZOLXV5cDM5MDZpTGlkMXBCaFFnU3ZjVng5TXRCTVU0Sk9iaUNmaWRXX05GZFF6UnFnTkpUd3laZ3VHNTRzVWhyQTFnNnVjYmxrUktKWWI1UFdYOWlDc2FZenNsenFYendlYm94VGwtVlZZZXJlR0NsSlB0aU9CTzJLTWc?oc=5","date":"2025-11-20","type":"deal","source":"Investor's Business Daily","summary":"Exact Sciences Catapults On $23 Billion Abbott Labs Buyout - Investor's Business Daily","headline":"Exact Sciences Catapults On $23 Billion Abbott Labs Buyout - Investor's Business Daily","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwAFBVV95cUxPNE9mQ2xFblhzSDR2VHVSUUp2VjJtemktT2gwcF9zNThscnZpVU02Q0FyLVdzRjJQOXBEZk9tSkhaRTBaOTk3NUltNmF0SGhnNGxULWZ0M0xzNnFNOGp0XzZrOVZlLTIwYXA5SHpCUndXMXBBSHRjZklWQ1R1R25pUGwzcF96T2lmTDBXSzM3Tm5YcGhOUHdiQVBqNlFRRFNPSzdZcnZ2UFliR3NHS2hhcmdFVmduNW5FMjlzYVg4MUg?oc=5","date":"2025-11-20","type":"deal","source":"TradingView","summary":"Is it too late to buy Exact Sciences stock after Abbott’s $21B deal? - TradingView","headline":"Is it too late to buy Exact Sciences stock after Abbott’s $21B deal?","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi5AFBVV95cUxQM3VOZHV5YTJYcTdxN2ZQQ0p0MXRBTTdDSEZEbnZyZEJwdlBnQ3NhbUR4VGJUVnBPTl8wYnZuSElYVDZhTnRMYUxLSFNNNmNDZFFBbHZfelBvZXJ0d0V2RDduWlRVQ3ZDR3I2NGZLQ2pMTkwyb211Y3hla2hhZ1RYcGItSEVuV2JhOS12QXlRQndwNkx1Qk5JZjl1bjNUNGtZWDR6a3dkZWZSa1JNTVU3X1d4VlE5WW9RQUVFMW5Pa25VZVNFZXFNQ19uT0p2UkpNQWFjNjQ2YXhwaGVTcG1kaDhZUDU?oc=5","date":"2025-11-20","type":"deal","source":"reuters.com","summary":"Abbott bets on cancer screening with $23 billion Exact Sciences deal - reuters.com","headline":"Abbott bets on cancer screening with $23 billion Exact Sciences deal","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi0wFBVV95cUxQRXhNeVZZemRvYXlTRUVMemFoRmd2WUNZYWtucjlQNVJQb1RkVjdYM2ZJWXdfeXRybmlZQnh4ZWhXWndDcEdTaHg3bzBrWkRnaTUxeG1CSHpKZV84ejBuMlhBeFBDY1Jrakd6SXZFaWlrbnJPOHVwTkYzNEtZamFmTFNfdjdITUxpbWRsdXJLTFlMTllRZlVCX0pPTG1QNTRLSGM2ejRUZXIzVm9nYWo4dHN0YmppUWtUVmMyb255SVl3azRNbXVaNTBMdmRZV3MyV0Uw?oc=5","date":"2025-11-19","type":"pipeline","source":"reuters.com","summary":"Abbott is weighing takeover of Exact Sciences, Bloomberg News reports - reuters.com","headline":"Abbott is weighing takeover of Exact Sciences, Bloomberg News reports","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiiAFBVV95cUxQbElzTTRrNUYzSDRKZ3gxeWVzREowTGZUS2xqbWtaeGR3MTlUaGJQd3pNRkxxUDNMTXNmZ0MtN21aMWtSQkwyNFNoRDg0YWg5T0hPbUVuOUNraHg3WjB3X3k4eEVSc091QXFHWWt4VUV0R3ZSU1N6c252eGcteFZfWXZ1TnNhNFhK?oc=5","date":"2025-11-10","type":"pipeline","source":"Yahoo Finance","summary":"Is Exact Sciences (EXAS) Stock Outpacing Its Medical Peers This Year? - Yahoo Finance","headline":"Is Exact Sciences (EXAS) Stock Outpacing Its Medical Peers This Year?","sentiment":"neutral"}],"patents":[],"drugCount":0,"phaseCounts":{},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":["Guardant Health","Foundation Medicine","Invitae"],"therapeuticFocus":["Oncology","Diagnostics"],"financials":{"source":"sec_edgar+yahoo","revenue":4144000,"revenuePeriod":"2013-12-31","revenueHistory":[{"value":4144000,"period":"2013-12-31"},{"value":1036000,"period":"2013-12-31"},{"value":1036000,"period":"2013-12-31"},{"value":1036000,"period":"2013-09-30"},{"value":1036000,"period":"2013-09-30"}],"grossProfit":2262755000,"grossProfitHistory":[{"period":"2025-12-31","value":2262755000},{"period":"2024-12-31","value":1918717000},{"period":"2023-12-31","value":1762202000},{"period":"2022-12-31","value":1422918000}],"rdSpend":522996000,"rdSpendHistory":[{"period":"2025-12-31","value":522996000},{"period":"2024-12-31","value":431210000},{"period":"2023-12-31","value":426927000},{"period":"2022-12-31","value":394191000}],"sgaSpend":1938857000,"operatingIncome":-199098000,"operatingIncomeHistory":[{"period":"2025-12-31","value":-199098000},{"period":"2024-12-31","value":-179243000},{"period":"2023-12-31","value":-214391000},{"period":"2022-12-31","value":-577542000}],"netIncome":-207949000,"netIncomeHistory":[{"period":"2025-12-31","value":-207949000},{"period":"2024-12-31","value":-1028857000},{"period":"2023-12-31","value":-204149000},{"period":"2022-12-31","value":-623506000}],"eps":-1.1,"epsHistory":[{"period":"2025-12-31","value":-1.1},{"period":"2024-12-31","value":-5.59},{"period":"2023-12-31","value":-1.13},{"period":"2022-12-31","value":-3.54}],"cash":955996000,"cashHistory":[{"period":"2025-12-31","value":955996000},{"period":"2024-12-31","value":600889000},{"period":"2023-12-31","value":605378000},{"period":"2022-12-31","value":242493000}],"totalAssets":5860629000,"totalLiabilities":3459577000,"totalDebt":2522699000,"equity":2401052000,"operatingCashflow":491438000,"operatingCashflowHistory":[{"period":"2025-12-31","value":491438000},{"period":"2024-12-31","value":210536000},{"period":"2023-12-31","value":156119000},{"period":"2022-12-31","value":-223559000}],"capex":-134656000,"capexHistory":[{"period":"2025-12-31","value":-134656000},{"period":"2024-12-31","value":-135989000},{"period":"2023-12-31","value":-124190000},{"period":"2022-12-31","value":-214462000}],"freeCashflow":356782000,"dividendsPaid":null,"buybacks":null,"employees":7100,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[{"sga":506520000,"ebit":-79933000,"ebitda":-23580000,"period":"2025-12-31","revenue":878381000,"epsBasic":null,"netIncome":-85955000,"rdExpense":191495000,"epsDiluted":null,"grossProfit":615826000,"operatingIncome":-82189000},{"sga":491641000,"ebit":-7968000,"ebitda":47914000,"period":"2025-09-30","revenue":850739000,"epsBasic":-0.1,"netIncome":-19594000,"rdExpense":117290000,"epsDiluted":-0.1,"grossProfit":583929000,"operatingIncome":-25002000},{"sga":455700000,"ebit":-2148000,"ebitda":53135000,"period":"2025-06-30","revenue":811085000,"epsBasic":-0.01,"netIncome":-1185000,"rdExpense":108901000,"epsDiluted":-0.01,"grossProfit":562453000,"operatingIncome":-2148000},{"sga":484996000,"ebit":-92172000,"ebitda":-38111000,"period":"2025-03-31","revenue":706785000,"epsBasic":-0.54,"netIncome":-101215000,"rdExpense":105310000,"epsDiluted":-0.54,"grossProfit":500547000,"operatingIncome":-89759000},{"sga":433600000,"ebit":-867720000,"ebitda":-814573000,"period":"2024-12-31","revenue":713424000,"epsBasic":-4.67,"netIncome":-864585000,"rdExpense":99617000,"epsDiluted":-4.67,"grossProfit":429224000,"operatingIncome":-38068000},{"sga":null,"ebit":null,"ebitda":null,"period":"2024-09-30","revenue":null,"epsBasic":-0.21,"netIncome":null,"rdExpense":null,"epsDiluted":-0.21,"grossProfit":null,"operatingIncome":null}]},"ciks":null,"lastFiledAt":null},"yahoo":{"currentPrice":104.91,"previousClose":104.91,"fiftyTwoWeekHigh":104.98,"fiftyTwoWeekLow":38.81,"fiftyTwoWeekRange":"","fiftyDayAverage":103.11,"twoHundredDayAverage":75.68,"beta":1.44,"enterpriseValue":21596198912,"forwardPE":55.2,"priceToBook":8.34,"priceToSales":6.17,"enterpriseToRevenue":6.65,"enterpriseToEbitda":302.23,"pegRatio":0,"ebitda":71456000,"ebitdaMargin":2.2,"freeCashflow":281868512,"operatingCashflow":491438016,"totalDebt":2534827008,"debtToEquity":105.6,"currentRatio":2.43,"returnOnAssets":-1.6,"returnOnEquity":-8.7,"analystRating":"","recommendationKey":"hold","numberOfAnalysts":10,"targetMeanPrice":106.3,"targetHighPrice":118,"targetLowPrice":105,"dividendRate":0,"payoutRatio":0,"fiveYearAvgDividendYield":0,"exDividendDate":0,"insiderHeldPercent":1.2,"institutionHeldPercent":86.5,"sharesOutstanding":190888211,"floatShares":188446751,"sharesShort":7401133,"shortRatio":3.23,"shortPercentOfFloat":3.9,"epsTrailing":-1.1,"epsForward":0,"revenuePerShare":17.21,"bookValue":12.58,"officers":[],"industry":"Diagnostics & Research","irWebsite":"http://investor.exactsciences.com","website":"https://www.exactsciences.com","phone":"608 284 5700"}}